We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...
Despite Wall Street's continued conservatism regarding its business prospects, Pfizer beat analysts' expectations for the second quarter of 2024. In addition to the raised full-year 2024 guidance, the ...
Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its ...
Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results